{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=23",
    "query": {
      "condition": "Multiple Diseases",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 12226,
    "total_pages": 1223,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T09:24:45.597Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00735371",
      "title": "Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "LDX 30 mg",
          "type": "DRUG"
        },
        {
          "name": "LDX 50 mg",
          "type": "DRUG"
        },
        {
          "name": "LDX 70 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 314,
      "start_date": "2008-10-08",
      "completion_date": "2009-04-06",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 45,
      "location_summary": "Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wildomar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735371"
    },
    {
      "nct_id": "NCT02901431",
      "title": "A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "RO5285119",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 339,
      "start_date": "2016-11-21",
      "completion_date": "2020-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-02-08",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 45,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02901431"
    },
    {
      "nct_id": "NCT03256045",
      "title": "Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Chemosensitivity Assay",
          "type": "OTHER"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Panobinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-02-08",
      "completion_date": "2021-02-05",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03256045"
    },
    {
      "nct_id": "NCT02494167",
      "title": "Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "MultiTAA-specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2016-02",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02494167"
    },
    {
      "nct_id": "NCT00099307",
      "title": "Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 94,
      "start_date": "2004-12-08",
      "completion_date": "2011-09-28",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099307"
    },
    {
      "nct_id": "NCT00704171",
      "title": "PleuraSeal Post Market Study (Europe)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lung Disease",
        "Pulmonary Lobectomy"
      ],
      "interventions": [
        {
          "name": "Standard Tissue Closure Techniques",
          "type": "PROCEDURE"
        },
        {
          "name": "PleuraSeal Lung Sealant System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Integra LifeSciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2008-01",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 1,
      "location_summary": "Bedford, Massachusetts",
      "locations": [
        {
          "city": "Bedford",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00704171"
    },
    {
      "nct_id": "NCT02082977",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK2816126",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2014-04-24",
      "completion_date": "2017-06-20",
      "has_results": true,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082977"
    },
    {
      "nct_id": "NCT02128230",
      "title": "UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "myPRS",
          "type": "DEVICE"
        },
        {
          "name": "Induction 1 - MEL-10+CFZ-TD-PACE",
          "type": "DRUG"
        },
        {
          "name": "First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)",
          "type": "DRUG"
        },
        {
          "name": "Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)",
          "type": "DRUG"
        },
        {
          "name": "Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)",
          "type": "DRUG"
        },
        {
          "name": "Consolidation - CFZ-TD-PACE",
          "type": "DRUG"
        },
        {
          "name": "Maintenance - CFZ-R(T)-D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-06-10",
      "completion_date": "2019-02-19",
      "has_results": true,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02128230"
    },
    {
      "nct_id": "NCT03236428",
      "title": "Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Monoclonal Gammopathy",
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-11-24",
      "completion_date": "2026-10-04",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 6,
      "location_summary": "Monterey, California • Denver, Colorado • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03236428"
    },
    {
      "nct_id": "NCT04177771",
      "title": "A Clinical Study to Evaluate The Safety and Effectiveness of The RxSight Light Adjustable Lens (LAL) In Subjects Desiring an Extended Depth of Focus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Aphakia",
        "Cataract",
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population",
          "type": "DEVICE"
        },
        {
          "name": "SofPort LI61AO IOL",
          "type": "DEVICE"
        },
        {
          "name": "Tecnis ZCB00 or ZTC150 IOL",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "RxSight, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-11-15",
      "completion_date": "2021-12-20",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-11-07T09:24:45.597Z",
      "location_count": 1,
      "location_summary": "Fayetteville, Arkansas",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177771"
    }
  ]
}